GlassScriptPhysician profile
Ronald S Weber
NPI 1174520670
$1,434.55
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $448 · 2022: $298.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $250.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $173.72 | 2019-2020 | |
| Alcon Vision LLC | $154.73 | 2019-2020 | |
| Sight Sciences, INC. | $124.98 | 2022 | |
| Rxsight INC | $124.95 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.09 | 2020 | |
| Novartis Pharmaceuticals Corporation | $110.36 | 2019-2020 | |
| Allergan, INC. | $92.83 | 2020 | |
| Glaukos Corporation | $78.13 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $59.50 | 2019-2020 | |
| Abbvie INC. | $48.01 | 2022 | |
| Ocular Therapeutix, INC. | $23.64 | 2019 | |
| Shire North American Group INC | $21.37 | 2019 | |
| Eyevance Pharmaceuticals LLC | $18.92 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $17.01 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $15.31 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.